{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-046849","form_type":"8-K","ticker":"CDT","cik":"0001896212","company_name":"CDT Equity Inc.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.292024+00:00","generated_at":"2026-05-29T22:41:31.066582+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Conduit Pharma appoints director Fry (420K options); amends CFO pay (£400K, 40% bonus) and quorum rule","bullets":["Simon Fry appointed as director effective Dec 18, 2024; receives initial option for 420,000 common shares.","CFO James Bligh's employment amendment: £400K base salary, discretionary bonus up to 40%, 6-month notice.","Bylaws amended: quorum reduced from majority to one-third voting power, effective after 2024 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-046849","json":"https://secwatch.observer/filing/0001493152-24-046849.json","markdown":"https://secwatch.observer/filing/0001493152-24-046849.md","text":"https://secwatch.observer/filing/0001493152-24-046849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:41:31.066582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f4142d9a2","claim":"Simon Fry was appointed as director at CDT Equity Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0000860413-26-000048","ticker":"FIBK","company_name":"FIRST INTERSTATE BANCSYSTEM INC","filed_at":"2026-05-29T20:26:09+00:00","headline":"First Interstate BancSystem: three directors retire per age policy; charter amended to plurality voting","event_type":"leadership","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 5.03, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000860413-26-000048","json":"https://secwatch.observer/filing/0000860413-26-000048.json","markdown":"https://secwatch.observer/filing/0000860413-26-000048.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/860413/000086041326000048/0000860413-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/860413/000086041326000048/fibk-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"on May 27, 2026, each of Ms. Patricia L. Moss and Messrs. David L. Jahnke and Stephen M. Lacy, each having reached the retirement age of 72, was deemed to have retired and resigned automatically from the Company’s Board of Directors","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/860413/000086041326000048/0000860413-26-000048-index.htm"}},{"accession":"0001850902-26-000011","ticker":"TKNO","company_name":"Alpha Teknova, Inc.","filed_at":"2026-06-01T21:22:10+00:00","headline":"Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor","event_type":"leadership","sec_items":["5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001850902-26-000011","json":"https://secwatch.observer/filing/0001850902-26-000011.json","markdown":"https://secwatch.observer/filing/0001850902-26-000011.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/0001850902-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/tkno-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"On May 27, 2026, Irene Davis, a member of the Board of Directors (the “Board”) of Alpha Teknova, Inc. (the “Company”) and a member of the Nominating and Corporate Governance Committee, notified the Company of her intention not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “Meeting”) and to retire from the Board and all committees thereof, effective upon the date of the Meeting.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/0001850902-26-000011-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0001477932-26-003559","ticker":"JOB","company_name":"GEE Group Inc.","filed_at":"2026-06-01T20:47:44+00:00","headline":"Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003559","json":"https://secwatch.observer/filing/0001477932-26-003559.json","markdown":"https://secwatch.observer/filing/0001477932-26-003559.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/job_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0002064307-26-000007","ticker":"LOGC","company_name":"ContextLogic Holdings Inc.","filed_at":"2026-06-01T20:15:17+00:00","headline":"ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002064307-26-000007","json":"https://secwatch.observer/filing/0002064307-26-000007.json","markdown":"https://secwatch.observer/filing/0002064307-26-000007.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/logc-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm"}},{"accession":"0001104659-26-068929","ticker":"VMI","company_name":"VALMONT INDUSTRIES INC","filed_at":"2026-06-01T20:15:13+00:00","headline":"Former CFO Thomas Liguori enters separation agreement; $4.9M retirement benefits","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068929","json":"https://secwatch.observer/filing/0001104659-26-068929.json","markdown":"https://secwatch.observer/filing/0001104659-26-068929.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/vmi-20260526x8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"Valmont Industries Inc. previously reported the appointment of John Schwietz as Valmont’s Executive Vice President and Chief Financial Officer and Corporate Secretary, effective April 8, 2026, to succeed Thomas Liguori.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm"}},{"accession":"0001104659-26-068891","ticker":"PSQH","company_name":"PSQ Holdings, Inc.","filed_at":"2026-06-01T20:02:28+00:00","headline":"PSQ Holdings SVP of People Michael Hebert resigns; severance of $137,500","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068891","json":"https://secwatch.observer/filing/0001104659-26-068891.json","markdown":"https://secwatch.observer/filing/0001104659-26-068891.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847064/000110465926068891/0001104659-26-068891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847064/000110465926068891/tm2616483d1_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm","comparable_excerpt":"On May 26, 2026, Michael Hebert resigned from his position of Senior Vice President of People of PSQ Holdings, Inc. (the “Company”), effective May 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1847064/000110465926068891/0001104659-26-068891-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}